BS_0QYS36NR
Ependymoma NOS
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ependymoma NOS
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ependymoma NOS
- overall_survival_months
- 13.66622864651774
- age_years
- 0.923
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.663
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.643
- IL6_JAK_STAT3_SIGNALING+0.616
- INFLAMMATORY_RESPONSE+0.603
- ANGIOGENESIS+0.592
- ALLOGRAFT_REJECTION+0.560
- INTERFERON_GAMMA_RESPONSE+0.556
- COAGULATION+0.535
- IL2_STAT5_SIGNALING+0.498
- INTERFERON_ALPHA_RESPONSE+0.493
Top 10 suppressed
- PROTEIN_SECRETION-0.438
- OXIDATIVE_PHOSPHORYLATION-0.365
- MYC_TARGETS_V1-0.316
- MITOTIC_SPINDLE-0.225
- E2F_TARGETS-0.201
- DNA_REPAIR-0.164
- G2M_CHECKPOINT-0.151
- UNFOLDED_PROTEIN_RESPONSE-0.120
- FATTY_ACID_METABOLISM-0.090
- PEROXISOME-0.074
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0QYS36NR | EPN | EPN Tumor | 0.982 |
| 2 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.936 |
| 3 | BS_TK84K675 | high-grade glioma | — | 0.934 |
| 4 | SRR1455369 | GTEX | — | 0.934 |
| 5 | BS_KXMYBQ6N | EPN | EPN Tumor | 0.931 |
| 6 | BS_769BDPDB | pilocytic astrocytoma | — | 0.930 |
| 7 | 02faba9d-8eda-4967-995d-61a0c13b843c | — | — | 0.930 |
| 8 | BS_PJPGVD62 | Ependymoma NOS | — | 0.929 |
| 9 | BS_ZVZDDW2G | pleomorphic xanthoastrocytoma(PXA) | — | 0.926 |
| 10 | BS_4T0HPZDC | Posterior Fossa Ependymoma | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.663 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.643 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.616 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.603 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.592 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.556 | Idelalisib | — uncovered |
| COAGULATION | 0.535 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.498 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.493 | Inavolisib | — uncovered |
| COMPLEMENT | 0.475 | Inavolisib | — uncovered |
| HYPOXIA | 0.475 | Idelalisib | — uncovered |
| APOPTOSIS | 0.461 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.402 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.393 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.390 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.382 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.379 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.367 | Temsirolimus | — uncovered |